Abstract
In the present study, the antitumor activity of activated recombinant human anti-Mullerian hormone (rAMH) against the NBL-7 and OVCAR3 cell lines was investigated. It was shown that the hormone contained in highly purified preparations not only has the ability to bind to the recombinant type II receptor (MISRII), but also possesses a cytotoxic effect against cells expressing MISRII. The obtained data may underlie the basis for the development of the first domestic anticancer drug based on activated rAMH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
